

SUCCESS OF IKONISYS' INITIAL PUBLIC OFFERING ON EURONEXT GROWTH® PARIS

- Offering price set at 5.75 euros per share
- Capital increase of 4.0 million euros
- Demand from individual investors: 0.9 million euros
- Market capitalization of approximately 55 million euros (post capital increase)
- Shares will begin trading on Euronext Growth® Paris on July 19, 2021 (ISIN: FR00140048X2 / Ticker: ALIKO)

Paris, July 13, 2021 – Ikonisys SA (hereafter “Ikonisys” or the “Company”), a company specializing in the early and accurate detection of cancers with a unique fully-automated solution for medical analysis labs, announces the success of its Initial Public Offering on the Euronext Growth® multilateral trading facility in Paris (ISIN: **FR00140048X2** / Ticker: **ALIKO**).

The distribution of the shares offered within the framework of the Company’s IPO was carried out via a global offer (the “Offer”), comprising:

- a public offering in France in the form of an open price offer, primarily intended for physical persons (the “OPO”);
- a global placement primarily aimed at institutional investors (the “Global Placement”) comprising:
 - a placement in France; and
 - an international private placement in selected countries (notably excluding the USA, Canada, Australia and Japan).

Mario Crovetto, CEO of Ikonisys, says: *“I would like to wholeheartedly thank all the shareholders, both individual and institutional, who have put their trust in us by contributing to the success of this Initial Public Offering. I would also like to warmly thank our members of staff and our clients who, through their commitment and trust, drive the Company’s success day in, day out. Ikonisys has just reached a new milestone in its development through this IPO on Euronext Growth Paris. We will be able to benefit from the depth and vibrancy of the French MedTech ecosystem, one of the world’s most dynamic. The funds raised will allow us to accelerate our development and, in particular, the commercialization in the United States and Europe of our new platform, Ikoniscope20, latest generation digital microscope that notably allows the automated identification of circulating tumor cells (CTC). These new financial resources will also support the ongoing financing of R&D aimed at maintaining our platform’s technological leadership. You will have understood that the Ikonisys adventure is just starting and a new chapter in our history is beginning today”.*

Offering Price

The Company's Board of Directors met today and set the price within the framework of the OPO and the Global Placement at €5.75 per share (the "Offering Price").

Reminder of the purpose of the funds raised: finance the Company's commercial strategy and the continuation of its R&D efforts

- **65% will be used to accelerate commercial development in the United States and to deploy the commercial development roadmap in Europe;**
- **20% will be used to finance R&D to enhance the Ikoniscope20 platform;**
- **15% will be used to finance working capital requirements.**

Size of the Offering

The initial public offering has enabled the Company to carry out a capital increase of 4.0 million euros via the issuance of 700,000 new ordinary shares.

The number of ordinary shares allocated within the framework of the Offering is as follows:

- 544,044 ordinary shares allocated within the framework of the Global Placement, representing 3.1 million euros, i.e. 78% of the total number of shares allocated;
- 155,956 ordinary shares allocated within the framework of the OPO, representing 896,747 euros, i.e. 22% of the total number of shares allocated. Within the framework of the OPO, A1 orders (from 1 share to 250 shares included) will be fully served and A2 orders (beyond 250 shares) will be 96% served.

Based on the Offering Price and the issuance of 700,000 new ordinary shares, Ikonisys' market capitalization will be approximately 55 million euros following the Offering. The free float represents 7,3% of the Company's share capital.

Abstention and lock-up commitments

Abstention commitment by the Company: 3 months from the date of settlement-delivery of the new shares.

Lock-up commitment by Cambria Co-Investment Fund and Cambria Equity Partners LP: 9 months from the date of settlement-delivery of the new shares for 100% of the shares held and a further 3 months for 80% of the shares held.

Lock-up commitment by MC Consulting S.r.l.: 12 months from the date of settlement-delivery of the new shares for 100% of the shares held.

This press release may not be published, distributed or circulated, either directly or indirectly, in the United States, Australia, Canada or Japan.

Completion of the contribution of all Ikonisys S.r.l. shares to the Company

Within the framework of the Company's initial public offering, the Company's shareholders today contributed all their holdings in Italian company Ikonisys S.r.l. (the "**Contribution**"), which is henceforth 100% owned by the Company.

The contribution agreement signed on June 15, 2021 between the Company's shareholders provided (i) that the Contribution would be valued on the basis of the subscription price of the Ikonisys shares to be issued within the framework of the admission to trading of Ikonisys shares on Euronext Growth Paris, and (ii) that the completion of the Contribution would notably be subject to the publication, immediately following the setting of the share subscription price within the framework of the OPO and the Global Placement by the Company's Board of Directors, of a supplementary report by the contributions auditor concluding – given the valuation of the Contribution on the basis of the share subscription price within the framework of the initial public offering – that the Contribution is not overvalued.

In this respect, the contributions auditor concluded, in its supplementary report published today, that: *"On the basis of our work and on the date of this report, we are of the opinion that the agreed value of the contributions, i.e. 50,388,555.25 euros, is not overvalued, and as a consequence is at least equal to the nominal value of the shares to be issued by the recipient company of the contributions, increased by the contribution share premium"*.

The Contribution was immediately completed following the definitive setting of the price of the Company's shares by the Board of Directors within the framework of the Initial Public Offering.

Breakdown of share capital and voting rights following the Offering

Prior to and following the Offering, the share capital and voting rights of the Company will be allocated as follows:

Shareholders	Before the Offering		After the Offering	
	Number of shares	% of share capital and voting rights	Number of shares	% of share capital and voting rights
Cambria Co-Invest. Fund LP	5,268,989	60.00%	5,268,989	55.57%
Cambria Equity Partners, LP	3,161,274	36.00%	3,161,274	33.34%
MC Consulting S.r.l.*	351,464	4.00%	351,464	3.71%
Free float	-	-	700,000	7.38%
TOTAL	8,781,727	100%	9,481,727	100%

* Holding company of Mr. Mario Crovetto, CEO of Ikonisys.

Indicative schedule

July 16, 2021	Settlement-delivery of the OPO and the Global Placement
July 19, 2021	The Company's shares begin trading on the Euronext Growth market in Paris on a listing line called "ikonisys"

This press release may not be published, distributed or circulated, either directly or indirectly, in the United States, Australia, Canada or Japan.



Characteristics of the shares

Name

IKONISYS

ISIN

FR00140048X2

Ticker

ALIKO

Compartment

Euronext Growth Paris

Sector of activity

NAF code: 4646Z

ICB classification: 20102010 – Medical Equipment

LEI code: 9695000B742KPNDQ4D05

Partners of the Operation



Listing Sponsor, Investment Service Provider and Bookrunner



Legal Counsel for the Operation



Investor Relations



Auditors

Eligibility of the Offering for PEA and “PME-ETI” PEA equity savings plans

The Company announces that it complies with the eligibility criteria for French “PME-ETI” PEA equity savings plans. As a result, the Company’s shares can be fully incorporated within PEA and “PME-ETI” PEA accounts, which enjoy the same tax benefits as the traditional PEA plan*.

Availability of the Information Document and risk factors

Copies of the Information Document are available free of charge upon request from the Company’s head offices, 62 rue de Caumartin, 75009 Paris, France. An electronic version is available on the Euronext website (www.euronext.com) and the Company’s website (www.ikonisys.com).

Ikonisys draws your attention to Chapter 4, “Risk Factors”, of the first part of the Information Document and to Chapter 1, “Risk Factors associated with the offered shares and with the Offering”, in the second part of the Information Document.

* These advantages are conditional and limited to available ceilings. Interested individuals are invited to contact their financial advisor.

This press release may not be published, distributed or circulated, either directly or indirectly, in the United States, Australia, Canada or Japan.



About Ikonisys

Ikonisys is a private cell-based diagnostics company based in New Haven, CT (USA) and Milan (Italy). The Company develops, produces and markets the Ikoniscope® proprietary platform designed to deliver highly accurate and reliable detection and analysis of rare cells. Using advanced molecular and immunological markers, the applications built by Ikonisys to be performed on the Ikoniscope® platform are extensively used in the United States and Europe to diagnose a variety of cancers. Ikonisys has received FDA clearance for several automated diagnostic applications, which are also marketed in Europe under CE certification.

For further information, please go to www.ikonisys.com

Contacts

Ikonisys

Alessandro Mauri
CFO
investors@ikonisys.com

NewCap

Olivier Bricaud / Louis-Victor Delouvrier
Investor Relations
ikonisys@newcap.eu
Tel.: +33 (0)1 44 71 94 92

NewCap

Nicolas Merigeau
Media Relations
ikonisys@newcap.eu
Tel.: +33 (0)1 44 71 94 98

Disclaimer

This press release contains forward-looking statements about the Company's prospects and development. These statements are sometimes identified by the use of the future tense, the conditional tense and forward-looking words such as "believe", "aim to", "expect", "intend", "estimate", "believe", "should", "could", "would" or "will" or, where appropriate, the negative of these terms or any other similar variants or expressions. This information is not historical data and should not be construed as a guarantee that the facts and data set forth will occur. This information is based on data, assumptions and estimates considered reasonable by the Company. It is subject to change or modification due to uncertainties relating to the economic, financial, competitive and regulatory environment. This information contains data relating to the Company's intentions, estimates and objectives concerning, in particular, the market, strategy, growth, results, financial situation and cash flow of the Company. The forward-looking information contained in this press release is made only as of the date of this press release. The Company does not undertake to update any forward-looking information contained in this press release, except as required by applicable law or regulation. The Company operates in a competitive and rapidly changing environment and therefore cannot anticipate all of the risks, uncertainties or other factors that may affect its business, their potential impact on its business or the extent to which the materialization of any one risk or combination of risks could cause results to differ materially from those expressed in any forward-looking information, it being recalled that none of this forward-looking information constitutes a guarantee of actual results.